{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:23:20Z","timestamp":1772781800578,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T00:00:00Z","timestamp":1429056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T00:00:00Z","timestamp":1429056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Intravenous (IV) injection of mesenchymal stem cells (MSCs) is used to treat systemic human diseases and disorders but is not routinely used in equine therapy. In horses, MSCs are isolated primarily from adipose tissue (AT) or bone marrow (BM) and used for treatment of orthopedic injuries through one or more local injections. The objective of this study was to determine the safety and lymphocyte response to multiple allogeneic IV injections of either AT-derived MSCs (AT-MSCs) or BM-derived MSCs (BM-MSCs) to healthy horses.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>We injected three doses of 25\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> allogeneic MSCs from either AT or BM (a total of 75\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> MSCs per horse) into five and five, respectively, healthy horses. Horses were followed up for 35\u00a0days after the first MSC infusion. We evaluated host inflammatory and immune response, including total leukocyte numbers, serum cytokine concentration, and splenic lymphocyte subsets.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Repeated injection of allogeneic AT-MSCs or BM-MSCs did not elicit any clinical adverse effects. Repeated BM-MSC injection resulted in increased blood CD8<jats:sup>+<\/jats:sup> T-cell numbers. Multiple BM-MSC injections also increased splenic regulatory T cell numbers compared with AT-MSC-injected horses but not controls.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>These data demonstrate that multiple IV injections of allogeneic MSCs are well tolerated by healthy horses. No clinical signs or clinico-pathologic measurements of organ toxicity or systemic inflammatory response were recorded. Increased numbers of circulating CD8<jats:sup>+<\/jats:sup> T cells after multiple IV injections of allogeneic BM-MSCs may indicate a mild allo-antigen-directed cytotoxic response. Safety and efficacy of allogeneic MSC IV infusions in sick horses remain to be determined.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13287-015-0050-0","type":"journal-article","created":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T23:02:30Z","timestamp":1428706950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Multiple intravenous injections of allogeneic equine mesenchymal stem cells do not induce a systemic inflammatory response but do alter lymphocyte subsets in healthy horses"],"prefix":"10.1186","volume":"6","author":[{"given":"Amir","family":"Kol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua A","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle D","family":"Carrade Holt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A","family":"Gillette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie K","family":"Bohannon-Worsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah M","family":"Puchalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi J","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlin C","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna L","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dori L","family":"Borjesson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,15]]},"reference":[{"key":"50_CR1","first-page":"1","volume":"63","author":"DD Carrade","year":"2013","unstructured":"Carrade DD, Borjesson DL. Immunomodulation by mesenchymal stem cells in veterinary species. Comparative Med. 2013;63:1\u201311.","journal-title":"Comparative Med"},{"key":"50_CR2","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1634\/stemcells.2005-0342","volume":"24","author":"S Kern","year":"2006","unstructured":"Kern S, Eichler H, Stoeve J, Kl\u00fcter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24:1294\u2013301.","journal-title":"Stem Cells"},{"key":"50_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3727\/215517912X647217","volume":"4","author":"DD Carrade","year":"2012","unstructured":"Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells. Cell Med. 2012;4:1\u201311.","journal-title":"Cell Med"},{"key":"50_CR4","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.tvjl.2013.04.018","volume":"197","author":"LV Schnabel","year":"2013","unstructured":"Schnabel LV, Fortier LA, Wayne McIlwraith C, Nobert KM. Therapeutic use of stem cells in horses: Which type, how, and when? Vet J. 2013;197:570\u20137.","journal-title":"Vet J"},{"key":"50_CR5","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3109\/14653249.2011.602338","volume":"13","author":"DD Carrade","year":"2011","unstructured":"Carrade DD, Affolter VK, Outerbridge CA, Watson JL, Galuppo LL, Buerchler S, et al. Intradermal injections of equine allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit immediate or delayed hypersensitivity reactions. Cytotherapy. 2011;13:1180\u201392.","journal-title":"Cytotherapy"},{"key":"50_CR6","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/jor.22338","volume":"31","author":"P Becerra","year":"2013","unstructured":"Becerra P, Vald\u00e9s V\u00e1zquez MA, Dudhia J, Fiske-Jackson AR, Neves F, Hartman NG, et al. Distribution of injected technetium99m-labeled mesenchymal stem cells in horses with naturally occurring tendinopathy. J Orthop Res. 2013;31:1096\u2013102.","journal-title":"J Orthop Res"},{"key":"50_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3109\/14653249.2010.536213","volume":"13","author":"DD Carrade","year":"2010","unstructured":"Carrade DD, Owens SD, Galuppo LD, Vidal MA, Ferraro GL, Librach F, et al. Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses. Cytotherapy. 2010;13:419\u201330.","journal-title":"Cytotherapy"},{"key":"50_CR8","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/j.jacc.2009.06.055","volume":"54","author":"JM Hare","year":"2009","unstructured":"Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial I infarction. J Am Coll Cardiol. 2009;54:2277\u201386.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cgh.2013.06.021","volume":"1","author":"GM Forbes","year":"2014","unstructured":"Forbes GM, Sturm MJ, Leong RW, Sparrow MP, Segarajasingam D, Cummins AG, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn\u2019s disease refractory to biologic therapy. Clin Gastroenterol H. 2014;1:64\u201371.","journal-title":"Clin Gastroenterol H"},{"key":"50_CR10","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1097\/QAD.0b013e32835fab77","volume":"27","author":"Z Zhang","year":"2013","unstructured":"Zhang Z, Fu J, Xu X, Wang S, Xu R, Zhao M, et al. Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients. AIDS. 2013;27:1283\u201393.","journal-title":"AIDS"},{"key":"50_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2174\/1574888X09666140220003847","volume":"9","author":"S Broeckx","year":"2014","unstructured":"Broeckx S, Borena BM, Zimmerman M, Marien T, Seys B, Suls M, et al. Intravenous application of allogenic peripheral blood-derived mesenchymal stem cells: a safety assessment in 291 equine recipients. Curr Stem Cell Res Ther. 2014;9:452\u20137.","journal-title":"Curr Stem Cell Res Ther"},{"key":"50_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/blood-2005-07-2657","volume":"107","author":"A Corcione","year":"2006","unstructured":"Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107:367\u201372.","journal-title":"Blood"},{"key":"50_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.exphem.2007.11.007","volume":"36","author":"M Di Ianni","year":"2008","unstructured":"Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol. 2008;36:309\u201318.","journal-title":"Exp Hematol"},{"key":"50_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/scd.2007.0175","volume":"17","author":"T Schink\u00f6the","year":"2008","unstructured":"Schink\u00f6the T, Bloch W, Schmidt A. In vitro secreting profile of human mesenchymal stem cells. Stem Cell Dev. 2008;17:199\u2013206.","journal-title":"Stem Cell Dev"},{"key":"50_CR15","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1089\/scd.2013.0537","volume":"23","author":"DD Carrade Holt","year":"2014","unstructured":"Carrade Holt DD, Wood JA, Granick JL, Walker NJ, Clark KC, Borjesson DL. Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source. Stem Cells Dev. 2014;23:1258\u201365.","journal-title":"Stem Cells Dev"},{"key":"50_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/scrt402","volume":"5","author":"LV Schnabel","year":"2014","unstructured":"Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJ, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro. Stem Cell Res Ther. 2014;5:13.","journal-title":"Stem Cell Res Ther"},{"key":"50_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3727\/000000006783981503","volume":"15","author":"KJ Beggs","year":"2006","unstructured":"Beggs KJ, Lyubimov A, Borneman JN, Bartholomew A, Moseley A, Dodds R, et al. Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant. 2006;15:711\u201321.","journal-title":"Cell Transplant"},{"key":"50_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.vetimm.2009.05.006","volume":"132","author":"AB Burton","year":"2009","unstructured":"Burton AB, Wagner B, Erb HN, Ainsworth DM. Serum interleukin-6 (IL-6) and IL-10 concentrations in normal and septic neonatal foals. Vet Immunol Immunopathol. 2009;132:122\u20138.","journal-title":"Vet Immunol Immunopathol"},{"key":"50_CR19","first-page":"548","volume":"82","author":"M Blanchard-Channell","year":"1994","unstructured":"Blanchard-Channell M, Moore PF, Stott JL. Characterization of monoclonal antibodies specific for equine homologues of CD3 and CD5. Immunology. 1994;82:548\u201354.","journal-title":"Immunology"},{"key":"50_CR20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2746\/0425164044864589","volume":"36","author":"CL Stull","year":"2004","unstructured":"Stull CL, Spier SJ, Aldridge BM, Blanchard M, Stott JL. Immunological response to long-term transport stress in mature horses and effects of adaptogenic dietary supplementation as an immunomodulator. Equine Vet J. 2004;36:583\u20139.","journal-title":"Equine Vet J"},{"key":"50_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.vetimm.2011.07.021","volume":"145","author":"S Ibrahim","year":"2012","unstructured":"Ibrahim S, Steinbach F. Immunoprecipitation of equine CD molecules using anti-human MABs previously analyzed by flow cytometry and immunohistochemistry. Vet Immunol Immunopathol. 2012;145:7\u201313.","journal-title":"Vet Immunol Immunopathol"},{"key":"50_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.vetimm.2010.11.020","volume":"140","author":"MG Robbin","year":"2011","unstructured":"Robbin MG, Wagner B, Noronha LE, Antczak DF, de Mestre AM. Subpopulations of equine blood lymphocytes expressing regulatory T cell markers. Vet Immunol Immunopathol. 2011;140:90\u2013101.","journal-title":"Vet Immunol Immunopathol"},{"key":"50_CR23","first-page":"251","volume":"74","author":"DP Lunn","year":"1991","unstructured":"Lunn DP, Holmes MA, Duffus WP. Three monoclonal antibodies identifying antigens on all equine T lymphocytes, and two mutually exclusive T-lymphocyte subsets. Immunology. 1991;74:251\u20137.","journal-title":"Immunology"},{"key":"50_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.vetimm.2011.05.033","volume":"148","author":"E Hamza","year":"2012","unstructured":"Hamza E, Steinbach F, Marti E. CD4+ CD25+ T cells expressing FoxP3 in Icelandic horses affected with insect bite hypersensitivity. Vet Immunol Immunopathol. 2012;148:139\u201344.","journal-title":"Vet Immunol Immunopathol"},{"key":"50_CR25","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1136\/gut.2010.215152","volume":"59","author":"M Duijvestein","year":"2010","unstructured":"Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn\u2019s disease: results of a phase I study. Gut. 2010;59:1662\u20139.","journal-title":"Gut"},{"key":"50_CR26","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.2337\/db10-0136","volume":"59","author":"DM Berman","year":"2010","unstructured":"Berman DM, Willman MA, Han D, Kleiner G, Kenyon NM, Cabrera O, et al. Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates. Diabetes. 2010;59:2558\u201368.","journal-title":"Diabetes"},{"key":"50_CR27","first-page":"11","volume":"2012","author":"SK Kang","year":"2012","unstructured":"Kang SK, Shin IS, Ko MS, Jo JY, Ra JC. Journey of mesenchymal stem cells for homing: strategies to enhance efficacy and safety of stem cell therapy. Stem Cell Int. 2012;2012:11.","journal-title":"Stem Cell Int"},{"key":"50_CR28","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3748\/wjg.v18.i10.1048","volume":"18","author":"J-JL Wei Zhao","year":"2012","unstructured":"Wei Zhao J-JL, Da-Yong C, Xiao L, Lin-Ying Z, Yong H, Shu-Qiang Y, et al. Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World J Gastroenterol. 2012;18:1048\u201358.","journal-title":"World J Gastroenterol"},{"key":"50_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087238","volume":"9","author":"IA Isakova","year":"2014","unstructured":"Isakova IA, Lanclos C, Bruhn J, Kuroda MJ, Baker KC, Krishnappa V, et al. Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo. PLoS One. 2014;9, e87238.","journal-title":"PLoS One"},{"key":"50_CR30","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1111\/j.1582-4934.2011.01509.x","volume":"16","author":"S Schu","year":"2012","unstructured":"Schu S, Nosov M, O'Flynn L, Shaw G, Treacy O, Barry F, et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med. 2012;16:2094\u2013103.","journal-title":"J Cell Mol Med"},{"key":"50_CR31","doi-asserted-by":"publisher","first-page":"302","DOI":"10.4049\/jimmunol.0902007","volume":"185","author":"S Ghannam","year":"2010","unstructured":"Ghannam S, P\u00e8ne J, Moquet-Torcy G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol. 2010;185:302\u201312.","journal-title":"J Immunol"},{"key":"50_CR32","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1089\/scd.2011.0722","volume":"21","author":"M Strioga","year":"2012","unstructured":"Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cell Dev. 2012;21:2724\u201352.","journal-title":"Stem Cell Dev"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-015-0050-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-015-0050-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-015-0050-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-015-0050-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:24:16Z","timestamp":1728923056000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-015-0050-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,15]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1186\/s13287-015-0050-0","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,15]]},"assertion":[{"value":"2 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"73"}}